Home » Newsletters » BioWorld Science

BioWorld Science

March 18, 2021

View Archived Issues

Anelixis begins phase II study of immunomodulation with AT-1501 in islet cell transplant

Selexis and Pandion to advance development of PT-627

Ventyx initiates dosing in phase I study of VTX-958 for autoimmune diseases

CohBar selects CB5138-3 as lead candidate for IPF and other fibrotic diseases

FDA clears initiation of phase I study of Meissa's COVID-19 vaccine candidate MV-014-212

Therapeutics Solutions plans to use StemVacs to treat COVID-19

T-Cure enters clinical research agreement to support phase I study of KK-LC-1 TCR therapy

Updated interim data reported from phase I/II study of GTB-3550 TriKE

Induced blastocysts are model for earliest development stages

AbbVie presents first-in-human data for ABBV-3373

Immatics reports data updates from ongoing phase I studies of its ACTengine candidates

New results presented for oral formulation of milvexian

Phase III data for omidubicel versus standard UCB in high-risk hematologic malignancies

Chinese phase I study begins with LPM-3480392

Ide-cel induces responses in heavily pretreated patients with refractory/relapsed myeloma

Lipopolysaccharides induce neural repair sweet spot

Data flaws sink current AI models for COVID-19 diagnosis

High blood fats, sugars alter antigen processing

Translate Bio reports second interim analysis of phase I/II trial of MRT-5005 for cystic fibrosis

Phase III topline data reported from ARISE-3 trial of RGN-259 in dry eye

PDE4 inhibitors divulged by Hubei Bio-Pharmaceutical, Humanwell Healthcare

Hefei Institutes of Physical Sciences presents new PDGFR-alpha and/or PDGFR-beta inhibitors

New hydroxyacid oxidase 1 inhibitors discovered at OxaluRx

HBV caspid assembly inhibitors patented by Tibet Tiansheng Taifeng Pharmaceutical

Gilead describes compounds for Filoviridae virus infections

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for June 4, 2026.
ASCO 2026: A revolution in pancreatic cancer
BioWorld
At the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting, Revolution Medicines Inc. followed up its stellar top-line data with the details from the...
News in brief
BioWorld Asia
BioWorld Asia briefs for June 2, 2026
EASL 2026: Emerging liver disease targets to watch
BioWorld
At the recently concluded European Association for the Study of the Liver meeting, presentations underscored how increasingly granular insights into liver...
ASCO 2026: PD-(L)1 x VEGF bispecifics fight it out
BioWorld
Multiple companies are chasing Akeso Inc. and Summit Therapeutics Inc. in the battle to potentially dethrone Keytruda (pembrolizumab, Merck & Co. Inc.) as the top...